spironolactone has been researched along with bay 94-8862 in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 7 (41.18) | 2.80 |
| Authors | Studies |
|---|---|
| Piotrowski, DW | 1 |
| Álvarez de la Rosa, D; Gerona-Navarro, G; González-Muñiz, R; Martín-Martínez, M; Pérez-Gordillo, FL; Rodríguez, Y; Zhou, MM | 1 |
| Albrecht-Küpper, B; Bärfacker, L; Delbeck, M; Eitner, F; Hartmann, E; Kolkhof, P; Kretschmer, A; Schäfer, S; Steinke, W | 1 |
| Anker, SD; Böhm, M; Filippatos, G; Gheorghiade, M; Kim, SY; Kimmeskamp-Kirschbaum, N; Krum, H; Køber, L; Maggioni, AP; Nowack, C; Pieper, A; Pitt, B; Ponikowski, P; Voors, AA; Zannad, F | 1 |
| Amazit, L; Fagart, J; Fay, MR; Hillisch, A; Khan, JA; Kolkhof, P; Lamribet, K; Le Billan, F; Lombès, M; Rafestin-Oblin, ME; Viengchareun, S | 1 |
| Benz, V; Blumrich, A; Brix, S; Foryst-Ludwig, A; Grune, J; Höft, B; Kintscher, U; Klopfleisch, R; Kolkhof, P; Salatzki, J | 1 |
| Ajioka, M; Kato, M; Kim, SY; Kolkhof, P; Myoishi, M; Nowack, C; Sato, N; Shiga, T; Yamada, T | 1 |
| Filippatos, G; Jaisser, F; Kim, SY; Kolkhof, P; Nowack, C; Pitt, B | 1 |
| Chen, X; Shen, W; Wu, Q; Wu, T; Xu, G; Xu, X; Yang, P; Zhu, D | 1 |
| Battaglia, G; Fiorini, F; Granata, A; La Rosa, S; Maccarrone, R; Ocello, A; Randone, S | 1 |
| Ahmadian-Tehrani, A; Anderson, AS; Rico-Mesa, JS; White, A | 1 |
| Bolignano, D; Chung, EY; Natale, P; Navaneethan, SD; Palmer, SC; Ruospo, M; Strippoli, GF | 1 |
| Carceller, E; Fagart, J; Kolkhof, P; Le Billan, F; Lombès, M; Perrot, J; Travers, S; Viengchareun, S | 1 |
| Armani, A; Caprio, M; Feraco, A; Kolkhof, P; Limana, F; Marzolla, V | 1 |
| Lerma, EV; Wilson, DJ | 1 |
| Armani, A; Caprio, M; Infante, M; Marzolla, V; Rizzo, M | 1 |
| Misra, A; Singh, A; Singh, AK; Singh, R | 1 |
9 review(s) available for spironolactone and bay 94-8862
| Article | Year |
|---|---|
Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.
Topics: Animals; Diabetic Nephropathies; Drug Design; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid | 2012 |
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Topics: Animals; Cardio-Renal Syndrome; Diabetic Nephropathies; Endothelial Cells; Eplerenone; Fibroblasts; Heart Failure; Humans; Macrophages; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Myocytes, Cardiac; Myocytes, Smooth Muscle; Naphthyridines; Receptors, Mineralocorticoid; Spironolactone; Stroke Volume | 2017 |
Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Topics: Eplerenone; Heart Failure; Hospitalization; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Peptide, Brain; Network Meta-Analysis; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency; Spironolactone; Treatment Outcome | 2019 |
[Antifibrotic renal role of mineralcorticoid receptor antagonists].
Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Nephropathies; Eplerenone; Fibrosis; Heart; Heart Diseases; Homeostasis; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Naphthyridines; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Spironolactone | 2019 |
Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.
Topics: Diabetic Nephropathies; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridines; Spironolactone | 2020 |
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bias; Calcium Channel Blockers; Canrenone; Disease Progression; Eplerenone; Humans; Hyperkalemia; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Naphthyridines; Proteinuria; Randomized Controlled Trials as Topic; Spironolactone | 2020 |
Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridines; Potassium; Renal Insufficiency, Chronic; Spironolactone | 2022 |
Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Naphthyridines; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Spironolactone; Stroke Volume | 2022 |
Finerenone in diabetic kidney disease: A systematic review and critical appraisal.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Glycated Hemoglobin; Heart Failure; Humans; Hyperkalemia; Male; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Spironolactone | 2022 |
2 trial(s) available for spironolactone and bay 94-8862
| Article | Year |
|---|---|
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Agents; Natriuretic Peptide, Brain; Peptide Fragments; Renal Insufficiency, Chronic; Spironolactone | 2015 |
A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
Topics: Adult; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Hyperkalemia; Japan; Naphthyridines; Natriuretic Peptide, Brain; Patient Safety; Peptide Fragments; Renal Insufficiency, Chronic; Spironolactone | 2016 |
6 other study(ies) available for spironolactone and bay 94-8862
| Article | Year |
|---|---|
Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
Topics: Amino Acid Sequence; Animals; Benzoxazines; Dihydropyridines; Drug Discovery; Humans; Ligands; Macrolides; Mineralocorticoid Receptor Antagonists; Models, Molecular; Oxazolidinones; Peptides; Pyrazoles; Pyrroles; Receptors, Mineralocorticoid; Structure-Activity Relationship; Sulfonamides | 2017 |
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Topics: Animals; Autoradiography; Cardiomegaly; Disease Models, Animal; Eplerenone; Heart Failure; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Peptide, Brain; Peptide Fragments; Rats; Rats, Sprague-Dawley; Rats, Wistar; Spironolactone; Tissue Distribution | 2014 |
Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
Topics: Active Transport, Cell Nucleus; Aldosterone; Blotting, Western; Cell Line; Cell Nucleus; Chromatin Immunoprecipitation; Dose-Response Relationship, Drug; Down-Regulation; Epithelial Sodium Channels; HEK293 Cells; Humans; Kinetics; Microscopy, Fluorescence; Mutation; Naphthyridines; Nuclear Receptor Coactivator 1; Promoter Regions, Genetic; Protein Binding; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Transcriptional Activation | 2015 |
Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Eplerenone; Gene Expression; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Peptide, Brain; Spironolactone; Troponin T; Ventricular Remodeling | 2016 |
Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells.
Topics: Aldosterone; Chromatin Immunoprecipitation; Humans; Kidney; Naphthyridines; Real-Time Polymerase Chain Reaction; RNA-Seq; Sequence Analysis, RNA; Spironolactone; Transcriptome | 2021 |
Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists.
Topics: Adipose Tissue, Brown; Animals; Disease Models, Animal; Gene Expression Profiling; Insulin Resistance; Metabolic Diseases; Mice; Mineralocorticoid Receptor Antagonists; Naphthyridines; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Receptors, Adrenergic, beta-3; Receptors, Mineralocorticoid; Spironolactone; Uncoupling Protein 1 | 2022 |